Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].

Kardiologiia - 31 Jul 2022

Ageev F T, Ovchinnikov A G

Abstract excerpt

The article discusses the problem of improving the effectiveness of treatment of heart failure with preserved left ventricular ejection fraction (HFpEF). The relative "failure" of early studies with renin-angiotensin-aldosterone system inhibitors was largely due to the lack of understanding that patients with HFpEF represent a heterogeneous group with various etiological factors and pathogenetic mechanisms of the...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aminobutyrates
Share to Amyloidosis
Share to Angiotensin Receptor Antagonists

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Biphenyl Compounds

Share to Hypertrophy, Left Ventricular

Share to Natriuretic Peptide, Brain

Share to Stroke Volume

Share to Ventricular Function, Left

Source

Identifiers

PMID: 35989629
DOI: 10.18087/cardio.2022.7.n2058

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

[Treatment of patients with heart failure and preserved ejection fraction: reliance on clinical phenotypes].PMID 35989629Read ↗

Patient phenotype profiling in heart failure with preserved ejection fraction to guide therapeutic decision making. A scientific statement of the Heart Failure Association, the European Heart Rhythm Association of the European Society of Cardiology, and the European Society of Hypertension.Semantic proximity Read ↗

Heart Failure with Preserved Ejection Fraction: The Pathophysiological Mechanisms behind the Clinical Phenotypes and the Therapeutic Approach.Semantic proximity Read ↗

Towards a phenotype profiling of the patients with heart failure and preserved ejection fractionSemantic proximity Read ↗

Heart failure with preserved ejection fraction: Classification based upon phenotype is essential for diagnosis and treatment.Semantic proximity Read ↗

Phenotypic spectrum of heart failure with preserved ejection fraction.Semantic proximity Read ↗

Canadian Cardiovascular Society-Canadian Heart Failure Society Focused Clinical Practice Update of Patients With Differing Heart Failure Phenotypes.Semantic proximity Read ↗

Sacubitril/Valsartan as a Therapeutic Tool Across the Range of Heart Failure Phenotypes and Ejection Fraction SpectrumSemantic proximity Read ↗

Phenotype-Specific Treatment of Heart Failure With Preserved Ejection Fraction: A Multiorgan Roadmap.Semantic proximity Read ↗

Biological Phenotypes of Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

Key Phenotypes of Heart Failure with Preserved Ejection Fraction: Pathophysiologic Mechanisms and Potential Treatment Strategies.Semantic proximity Read ↗

Current gaps in HFpEF trials: Time to reconsider patients' selection and to target phenotypes.Semantic proximity Read ↗

Clinical Phenotypes in Heart Failure With Preserved Ejection Fraction.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.